Research progress of bisphosphonate and denosumab in bone health management of early breast cancer

VernacularTitle:双膦酸盐和地舒单抗在早期乳腺癌骨健康管理中的研究进展
Author: Shuqi CHEN ¹ ; Minghua CHE ; Wanli ZHANG ; Wenbin ZHOU ; Wei HE
Author Information

1. 南京医科大学第一附属医院内分泌科　210029
Publication Type:Journal Article
Keywords: Bisphosphonate; Denosumab; Early breast cancer; Bone loss; Adjuvant therapy
From: Chinese Journal of Endocrinology and Metabolism 2025;41(1):65-69
CountryChina
Language:Chinese
Abstract: Secondary osteoporosis is common in patients with early breast cancer, manifesting as low back pain, bone and joint symptoms, and osteoporotic fractures. Bisphosphonate and denosumab can reduce the incidence of fractures by minimizing bone loss, though they differ in efficacy, treatment course, and side effects. Patients should consider the pros and cons when selecting a drug. Recent studies also focus on decreasing the incidence of bone metastases. This article reviews recent advancements in the use of these two drugs for managing bone health in early breast cancer.